Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 7, 2001, Pages 1161-1170

  Pankiewicz, K W ^a  

^a PHARMASSET INC   (United States)

Author keywords

Antiviral; Cancer; Chemotherapy; Immunosuppression; IMPDH

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; ADENINE; ADENOSINE KINASE; ADENOSINE PHOSPHATE; ALPHA INTERFERON; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; BACTERIAL ENZYME; BENZAMIDE DERIVATIVE; BENZAMIDE RIBOSIDE; BISPHOSPHONIC ACID DERIVATIVE; DNA; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; INOSINE PHOSPHATE; MERIMEPODIB; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PURINE NUCLEOTIDE; PYRIDAZINE DERIVATIVE; RIBAVIRIN; RNA; STAUROSPORINE; TIAZOFURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CANCER; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; DNA SYNTHESIS; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MAMMAL; MOUSE; NEPHROTIC SYNDROME; NONHUMAN; NUCLEOTIDE METABOLISM; PARASITE; RHEUMATOID ARTHRITIS; RNA SYNTHESIS; SOLID TUMOR; SPECIES DIFFERENCE; TUMOR CELL; VIRUS INFECTION;

EID: 0034943602     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.7.1161     Document Type: Article

References (33)

1. Inosine 5′-monophosphate dehydrogenase is a rate-determining factor for p53-dependent growth regulation
2. Inosine monophosphate dehydrogenase: Consideration of structure, kinetics, and therapeutic potential
3. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNA
4. Characterization of human type I and type II IMP dehydrogenase
5. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene
6. Selective inhibition of human Molt-4 leukemia type II inosine 5′-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexana-2,4-diones
7. Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design
8. Drug selectivity is determined by coupling across the NAD site of IMP dehydrogenase
9. Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid
10. Conformational changes and stabilization of inosine 5′-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid
11. Kinetic mechanism of human inosine 5′-monophosphate dehydrogenase type II: Random addition of substrates and ordered release of products
12. Inhibition of IMPDH by mycophenolic acid: Dissection of forward and reverse pathways using capillary electrophoresis
13. Mycophenolic mofetil: Molecular mechanism of action
14. Characteristic and crystal structure of bacterial inosine 5′-monophosphate dehydrogenase
15. Differential splicing of Pneumocistis carinii f. sp. carinii inosine 5′-monophosphate dehydrogenase pre-mRNA
16. Crystal structure at 2.4 Å resolution of Borrelia burgdorferi inosine 5′-monophosphate dehydrogenase: Evidence of a substrate-induced hinged-lid motion by loop 6
17. Crystal structure of Tritrichomonas foetus inosine-5′-monophosphate dehydrogenase and the enzyme-product complex
18. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors
19. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of Hepatitis-induced serum alanine aminotransferase levels
20. The roles of conserved carboxylate residues in IMP dehydrogenase and identification of a transition state analog
21. Mechanism-based design of inosine 5′-monophosphate dehydrogenase inhibitors: Synthesis and biological activities of 5-ethynyl-1-β-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives
22. Human collorectal carcinoma cells in vitro as a means to assess the metabolism of analogues of mycophenolic acid
23. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
24. Vertex: A small bump in the road
25. A novel series of non-nucleoside inhibitors of inosine 5′-monophosphate dehydrogenase with immunosuppressive activity
26. Ribavirin, tiazofurin, selenazofurin: Mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase
27. Synthesis, conformational analysis, and biological activity of C-thioribonucleosides related to tiazofurin
28. A new C-nucleoside analogue of tiazofurin: Synthesis and biological evaluation 2-β-ribofuranosylimidazole-4-carbox-amide (imidazofurin)
29. Antitumor activity of benzamide riboside and its combination with cis-platin and staurosporine
30. Synthesis of nonhydrolyzable analogues of thiazole-4-carboxamide and benzamide adenine dinucleotide containing fluorine atom at the C2′ of adenine nucleoside: Induction of K562 differentiation and inosine inhibitory activity
31. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid
32. Synthesis of a methylenebis(phosphonate) analogue of mycophenolic adenine dinucleotide: A glucuronidation-resistant MAD analogue of NAD
33. Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants